Atara Biotherapeutics (NASDAQ:ATRA) Price Target Raised to $21.00

Atara Biotherapeutics (NASDAQ:ATRA - Free Report) had its target price lifted by Canaccord Genuity Group from $13.00 to $21.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the biotechnology company's stock.

Several other equities analysts have also recently issued reports on the company. The Goldman Sachs Group decreased their price target on Atara Biotherapeutics from $12.50 to $11.00 and set a "sell" rating on the stock in a report on Wednesday, July 17th. Mizuho upgraded Atara Biotherapeutics from a "neutral" rating to an "outperform" rating and reduced their price target for the company from $25.00 to $18.00 in a research note on Friday, August 16th. Finally, HC Wainwright restated a "neutral" rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $16.67.

Atara Biotherapeutics Price Performance

Atara Biotherapeutics stock traded up $2.59 during midday trading on Wednesday, hitting $14.26. The company's stock had a trading volume of 303,843 shares, compared to its average volume of 106,857. The stock's 50-day moving average price is $8.79 and its 200-day moving average price is $10.27. Atara Biotherapeutics has a 12 month low of $6.48 and a 12 month high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the previous year, the firm posted ($16.50) EPS. As a group, sell-side analysts anticipate that Atara Biotherapeutics will post -12.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics during the 2nd quarter worth $79,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics during the 2nd quarter worth about $53,000. FMR LLC lifted its position in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company's stock valued at $204,000 after acquiring an additional 7,381 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Atara Biotherapeutics by 8,916.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company's stock valued at $3,442,000 after buying an additional 4,903,159 shares during the last quarter. Finally, Redmile Group LLC increased its stake in shares of Atara Biotherapeutics by 1.7% during the 1st quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company's stock worth $6,429,000 after purchasing an additional 156,863 shares during the last quarter. Institutional investors and hedge funds own 70.90% of the company's stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.